Fortune Brands recently announced it will consolidate its U.S offices into one headquarters, taking over two of three office ...

A safety net health care provider has won a $10.3 million interim arbitration judgment against Eagan-based Prime Therapeutics over price-fixing allegations between the local pharmacy benefits ...

Arbitrator issued interim award and Injunction to prevent future wrongdoing by Prime Therapeutics in antitrust case brought by AIDS Healthcare Foundation Regarding AHF's arbitration victory over ...

Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Viking Therapeutics, Inc. Recent revisions tend to reflect the latest near-term business trends.

Elucidating the molecular signalling pathways that control expression of the MYCN oncoprotein and targeting these pathways with novel therapeutics is a major goal of the laboratory. We use a variety ...

However, Wall Street's enthusiasm for Summit Therapeutics appears to be justified. If ivonescimab fulfills its potential, Summit should be worth a lot more within a few years than it is today.

A confirmation in "early" 2025 that the company has developed a competitive subcutaneous formulation of Briumvi is another potential near-term catalyst for the stock. Further positives include the ...

EMERYVILLE, Calif., Jan. 13, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna, NASDAQ: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with ...

Tune Therapeutics’ co-founders, from left: Akira Matsuno, chief financial officer; Charles Gersbach; and Fyodor Urnov, who also serves on the startup’s scientific advisory board. (Tune Photos ...